Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LAUR | 8-K | bullish | 6/10 | Laureate Education reported Q3 2026 revenue of $485.1M (+21% YoY reported, +14% constant currency) and GAAP diluted EPS | Oct 29, 2026 |
| WTBA | 8-K | neutral | 5/10 | West Bancorporation reported Q3 2026 net income of $11.6 million ($0.67 diluted EPS), up 5.0% sequentially and 24.8% YoY | Oct 29, 2026 |
| TSAT | 6-K | bearish | 6/10 | Telesat reported Q3 2026 consolidated revenue of $81 million, a 20% decline YoY, and adjusted EBITDA of $12 million, a 7 | Oct 29, 2026 |
| FRFHF | 6-K | neutral | 4/10 | Fairfax Financial Holdings completed the sale of its 80% equity interest in Eurolife FFH Insurance Group Holdings S.A. t | Oct 29, 2026 |
| HOG | PRESS-RELEASE | bearish | 6/10 | Harley-Davidson reported Q3 2026 GAAP diluted EPS of $0.40, below the $0.47 consensus, and HDMC revenue of $964M, below | Oct 29, 2026 |
| LIN | 8-K | bullish | 6/10 | Linde reported Q3 2026 adjusted EPS of $4.59, beating the $4.52 consensus by 1.5%, and revenue of $9.404B, above the $9. | Oct 29, 2026 |
| CLX | DEFA14A | neutral | 3/10 | Clorox filed a DEFA14A supplement to its proxy statement disclosing the appointment of Fabian Garcia as CEO effective Ja | Oct 29, 2026 |
| OWL | 8-K | bullish | 6/10 | Blue Owl Capital reported Q3 2026 Fee-Related Earnings of $427.5M ($0.27 per adjusted share) and Distributable Earnings | Oct 29, 2026 |
| KYMR | 8-K | neutral | 5/10 | Kymera Therapeutics reported Q3 2026 results with no collaboration revenue ($0 vs $2.8M in Q3 2025) and a net loss of $1 | Oct 29, 2026 |
| AXTA | 8-K | bearish | 5/10 | Axalta reported Q3 2026 net sales of $1.311B, up 2% YoY, but Adjusted EBITDA fell 4% to $282M and Adjusted Diluted EPS d | Oct 29, 2026 |
| ALGM | 8-K | bullish | 6/10 | Allegro MicroSystems reported fiscal Q2 2027 revenue of $276.9M (+29% YoY) and non-GAAP EPS of $0.26, beating consensus | Oct 29, 2026 |
| HII | 8-K | bullish | 6/10 | HII reported record Q3 2026 revenue of $3.537B (+10.8% YoY) and diluted EPS of $5.48 (+48.9% YoY), both significantly ab | Oct 29, 2026 |
| CRTO | 8-K | neutral | 2/10 | Criteo announced the resignation of board member Edmond Mesrobian and the appointment of Jianchang 'JC' Mao as an indepe | Oct 29, 2026 |
| CLX | 8-K | neutral | 3/10 | Clorox appointed Fabian Garcia as CEO, effective January 5, 2027, succeeding Linda Rendle who is stepping down for healt | Oct 29, 2026 |
| WST | 8-K | bullish | 6/10 | West Pharmaceutical reported Q3 2026 net sales of $874.5M (+8.7% reported, +11.9% organic) and adjusted-diluted EPS of $ | Oct 29, 2026 |
| CSIQ | 6-K | bearish | 6/10 | Canadian Solar's majority-owned subsidiary CSI Solar reported a severe Q3 2026 earnings decline. Operating revenue fell | Oct 29, 2026 |
| BMY | 8-K | neutral | 5/10 | Bristol Myers Squibb reported Q3 2026 revenue of $13.07B (+7% YoY), above the $12.73B consensus, driven by 12% Growth Po | Oct 29, 2026 |
| BCYC | 8-K | neutral | 4/10 | Bicycle Therapeutics reported Q3 2026 net loss of $10.5M ($-0.15 per share), significantly narrower than the $59.1M loss | Oct 29, 2026 |
| TROW | 8-K | mixed | 5/10 | T. Rowe Price reported Q3 2026 adjusted EPS of $2.86, beating the $2.65 consensus by 7.9%, and revenue of $2.005B, above | Oct 29, 2026 |
| WPP | 6-K | bearish | 5/10 | WPP reported Q3 2026 revenue of £3,274m, up 0.5% YoY, but revenue less pass-through costs fell 2.1% LFL to £2,411m. The | Oct 29, 2026 |
| HWM | 8-K | bullish | 6/10 | Howmet Aerospace reported Q3 2026 revenue of $2.70 billion (up 29% YoY, organic growth 25%) and adjusted EPS of $1.46 (u | Oct 29, 2026 |
| ALT | 8-K | neutral | 3/10 | Altimmune drew $10.0 million (Tranche Three) from its existing $125.0 million loan facility with Hercules Capital, trigg | Oct 29, 2026 |
| LTH | 8-K | bullish | 6/10 | Life Time reported Q3 2026 revenue of $893.5M (+14.2% YoY) and diluted EPS of $0.46 (+2.2% YoY), both above consensus es | Oct 29, 2026 |
| CCC | PRESS-RELEASE | bullish | 6/10 | CCC reported Q3 2026 revenue of $294.1M (up 10.1% YoY) and GAAP diluted EPS of $0.05, beating the consensus estimate of | Oct 29, 2026 |
| MYE | 8-K | bearish | 5/10 | Myers Industries reported Q3 2026 net sales of $171.3M, up 8.1% YoY, but GAAP EPS from continuing operations fell to $0. | Oct 29, 2026 |
| PHAT | 8-K | bullish | 6/10 | Phathom Pharmaceuticals reported Q3 2026 net revenue of $84.7M, up 71% YoY and 14% sequentially, and generated positive | Oct 29, 2026 |
| MO | 8-K | neutral | 5/10 | Altria reported Q3 2026 adjusted diluted EPS of $1.52, in line with the $1.51 consensus, on net revenues of $6.13B (abov | Oct 29, 2026 |
| TSAT | 6-K | bearish | 6/10 | Telesat reported a net loss of $157.2M for Q3 2026 (vs. $121.1M loss in Q3 2025) and $866.7M for 9M 2026 (vs. $97.0M los | Oct 29, 2026 |
| INCY | 8-K | bullish | 6/10 | Incyte reported Q3 2026 total revenue of $1.56B (+14% YoY) and total net sales of $1.32B (+14% YoY), with Jakafi net sal | Oct 29, 2026 |
| NCLH | 8-K | neutral | 3/10 | Norwegian Cruise Line Holdings Ltd. announced the planned retirement of CFO Mark Kempa effective June 30, 2027, with a t | Oct 29, 2026 |